Literature DB >> 10947918

Predictors of bleeding complications after rescue coronary interventions.

H L Dauerman1, C Andreou, M A Perras, J S Spinner, D Lessard, B H Weiner.   

Abstract

The purpose of this study was to determine predictors of bleeding complications after current rescue coronary interventions including stenting and adjunctive platelet inhibitors. Previous studies of rescue angioplasty for thrombolytic failure have identified variable rates of bleeding complications with balloon angioplasty alone. Although coronary stents and glycoprotein 2b/3a inhibitors have been shown to improve outcome in a wide variety of coronary interventions, the impact of these therapies on bleeding complications after rescue coronary intervention has not been determined. From 1996 through 1998, we treated 108 consecutive patients with rescue coronary intervention (defined as attempted coronary intervention within 12 hours of thrombolysis for ongoing symptoms or electrocardiogram [ECG] changes) including conventional percutaneous transluminal coronary artery (PTCA), stenting (n = 45), and glycoprotein 2b/3a inhibitor use (n = 31). In-hospital clinical outcomes were obtained in all patients, and univariate and multivariate predictors of bleeding complications were identified. In hospital, moderate to severe bleeding complications occurred in 17.6% of the cohort, but the rate of severe bleeding complications (2.7%) and vascular repair (1.9%) were low. Independent predictors of bleeding complications were age > 60y, female gender, cardiogenic shock, and streptokinase use. Neither the delayed use of abciximab (on average 4 hours after thrombolytic therapy initiation) nor the use of rescue stenting were predictors of increased moderate to severe bleeding complications. Current rescue coronary intervention, including stents and platelet inhibitors, is associated with a low rate of severe bleeding complications. Moderate to severe bleeding complications were more common in selected subgroups of patients but not increased significantly by stenting or delayed abciximab use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947918     DOI: 10.1023/a:1018759024035

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

Review 1.  Importance of the pharmacological profile of thrombolytic agents in clinical practice.

Authors:  J S Alpert
Journal:  Am J Cardiol       Date:  1991-12-05       Impact factor: 2.778

2.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

Review 3.  Thrombolytic therapy: current status (1).

Authors:  V J Marder; S Sherry
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

4.  Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.

Authors:  D W Sundlof; P Rerkpattanapitat; N Wongpraparut; P Pathi; M N Kotler; L E Jacobs; G S Ledley; S Yazdanfar
Journal:  Am J Cardiol       Date:  1999-06-01       Impact factor: 2.778

5.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Authors:  S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

6.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

7.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

8.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

9.  A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction.

Authors:  W W O'Neill; R Weintraub; C L Grines; T B Meany; B R Brodie; H Z Friedman; R G Ramos; V Gangadharan; R N Levin; N Choksi
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  1 in total

1.  Bleeding complications after contemporary pharmacoinvasive therapy for ST elevation myocardial infarction.

Authors:  Matthew J Gutierrez; Atul Aggarwal; Kristin Gilbert; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.